Progress of Research on Programmed Death-1/Programmed Death Ligand-1 Inhibitors for HIV/AIDS with Cancer by DENG Changgang, ZHANG Wei, SUN Yanyu, LI Qisui, HUANG Wei, YUAN Jing

Subjects: “…pd-1/pd-l1 inhibitor…”
Get full text

Efficacy and Safety of TACE Combined with Lenvatinib and PD-(L)1 Inhibitor in the Treatment of Unresectable Hepatocellular Carcinoma: A Retrospective Study by Yang H, Yang T, Qiu G, Liu J

Subjects: Get full text

A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer by Jaydira Del Rivero, Jaydira Del Rivero, Renee N. Donahue, Jennifer L. Marté, Ann W. Gramza, Marijo Bilusic, Myrna Rauckhorst, Lisa Cordes, Maria J. Merino, William L. Dahut, Jeffrey Schlom, James L. Gulley, Ravi A. Madan

Subjects: Get full text

PD-1/L1 inhibitor plus chemotherapy in the treatment of sarcomas by Zhichao Tian, Weitao Yao

Subjects: Get full text

Case Report: Acute Myocarditis Due to PD-L1 Inhibitor Durvalumab Monotherapy in a Patient With Lung Squamous Cell Carcinoma by Bo Zhou, Manxiang Li, Tianjun Chen, Jianqing She

Subjects: Get full text

Case Report: Replacement of PD-1 inhibitors with PD-L1 inhibitors in the treatment of squamous non-small-cell lung carcinoma by Tong Wu, Yujun Li, Xiaonan Cui, Chunxia Zhang

Subjects: Get full text

BMS‐202, a PD‐1/PD‐L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways by Yuanyuan Cai, Min Xiao, Xinqing Li, Shanyu Zhou, Yangyang Sun, Wenyuan Yu, Tianlan Zhao

Subjects: Get full text

A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors by Congjun Zhang, Jingjing Li, Hongyang Wu, Wei Huang, Liangshan Da, Yuanyuan Shen, Guoping Sun

Subjects: Get full text

Safety of thoracic radiotherapy after PD‐(L)1 inhibitor treatment in patients with lung cancer by Yu Chen, Xinchao Liu, Zhaoqin Huang, Kaikai Zhao, Yao Wang, Fei Ren, Jinming Yu, Xiangjiao Meng

Subjects: Get full text

Clinical Analysis of Docetaxel Combined with PD-1/PD-L1 Inhibitor in Second-line Treatment of Advanced Non-small Cell Lung Cancer by Qing CHEN, Yan LI, Wenjie ZHANG, Shengjie YANG, Chen WANG, Qisen GUO, Wenna SHI

Subjects: Get full text

Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer by Yuchang Wang, Yuchang Wang, Yuchang Wang, Yuchang Wang, Rui Chen, Yue Wa, Yue Wa, Yue Wa, Yue Wa, Shikuan Ding, Shikuan Ding, Shikuan Ding, Shikuan Ding, Yijian Yang, Yijian Yang, Yijian Yang, Yijian Yang, Junbo Liao, Junbo Liao, Junbo Liao, Junbo Liao, Lei Tong, Lei Tong, Lei Tong, Lei Tong, Gelei Xiao, Gelei Xiao, Gelei Xiao, Gelei Xiao

Subjects: Get full text

Immune checkpoint inhibitors for urothelial carcinoma by Hyung Suk Kim, Ho Kyung Seo

Subjects: Get full text

Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial by Jie Chen, Chen Li, Yuanjie Cao, Li Zhu, Bailin Zhang, Jinqiang You, Hailing Hou, Jing Wang, Zhiyong Yuan

Subjects: Get full text

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC) by Wolfgang M. Brueckl, Joachim H. Ficker, Gloria Zeitler

Subjects: Get full text

The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer by Da Hyun Kang, Seong‐woo Choi, Pureum Sun, Chaeuk Chung, Dongil Park, Song‐I Lee, Jeong Suk Koh, Yoonjoo Kim, Jeong Eun Lee

Subjects: Get full text

Association of lymphocyte subsets percentage with prognosis for recurrent or metastatic nasopharyngeal carcinoma patients receiving PD-L1 inhibitors by Jianming Diao, Zhigong Wei, Yiyan Pei, Junyou Ge, Yan Qing, Youneng Wei, Ye Chen, Xingchen Peng

Subjects: Get full text

GSDME has prognostic and immunotherapeutic significance in residual hepatocellular carcinoma after insufficient radiofrequency ablation by Xuexia Liang, Qiaodan Liu, Shuqin Zhu, Zizi Li, Hui Chen, Zhongzhen Su

Subjects: Get full text

A Potential Off-Target Effect of the Wnt/β-Catenin Inhibitor KYA1797K: PD-L1 Binding and Checkpoint Inhibition by Xavier Thuru, Romain Magnez, Gérard Vergoten, Christian Bailly

Subjects: Get full text

Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A prelim... by Kang Wang, Yan-Jun Xiang, Hong-Ming Yu, Yu-Qiang Cheng, Zong-Han Liu, Jing-Ya Zhong, Shuang Feng, Qian-Zhi Ni, Qian-Zhi Ni, Hong-Fei Zhu, Wei-Wei Pan, Wei-Wei Pan, Jing-Jing Li, Chao Liang, Hong-Kun Zhou, Yan Meng, Wan Yee Lau, Wan Yee Lau, Shu-Qun Cheng, Shu-Qun Cheng, Shu-Qun Cheng, Shu-Qun Cheng

Subjects: “…PD-L1 inhibitor…”
Get full text

Does it fit in your pocket? economic burden of PD-1 inhibitors' toxicity in the supplementary health system: evidence from Brazil by Hugo Santos Duarte, Cassia Rita Pereira da Veiga, Claudimar Pereira da Veiga, Alberto Julius Alves Wainstein, Wesley Vieira da Silva, Ana Paula Drummond-Lage

Subjects: Get full text